Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in adults with chronic inducible urticaria inadequately controlled by H1 antihistamines
CTR20240112Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in chronic inducible urticaria (CIndU), symptomatic dermatographism (SD), Cold urticaria (CU), Cholinergic Urticaria (CU), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started Apr 2024; status: active.
02
Drugs
remibrutinib
03
Conditions
chronic inducible urticaria (CIndU)symptomatic dermatographism (SD)Cold urticaria (CU)Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on CTR20240112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240112.